EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Nassar, Amin
Adib, Elio
Feng, Jamie
Aredo, Jacqueline V.
Parikh, Kaushal
Harris, Jeremy Phillip
Manana, Ana I. Velazquez
Ragavan, Meera Vimala
Lin, Jessica Jiyeong
Piotrowska, Zofia
Fitzgerald, Bailey Gleason
Grohe, Christian
Sankar, Kamya
Neal, Joel W.
Wakelee, Heather A.
Shepherd, Frances A.
Herbst, Roy S.
Naqash, Abdul Rafeh
Goldberg, Sarah B.
Kim, So Yeon
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Stanford Canc Inst, Stanford, CA USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Calif Irvine, Orange, CA USA
[7] Univ Calif San Francisco, San Francisco, CA USA
[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Icahn Sch Med Mt Sinai, New York, NY USA
[11] ELK Berlin, Dept Resp Dis, Berlin, Germany
[12] Cedars Sinai Med Ctr, Los Angeles, CA USA
[13] Stanford Univ, Med Ctr, Stanford, CA USA
[14] Stanford Hosp & Clin, Stanford, CA USA
[15] Univ Hlth Network, Princess Margaret, Toronto, ON, Canada
[16] Yale New Haven, Yale Sch Med, Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[17] Univ Oklahoma Hlth Sci, Stephenson Canc Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8567
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [42] Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC)
    Henick, Brian S.
    Goldberg, Sarah B.
    Narayan, Azeet
    Rossi, Chiara
    Rodney, Simon
    Kole, Adam J.
    Politi, Katerina A.
    Gettinger, Scott N.
    Herbst, Roy S.
    Patel, Abhijit
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Fenizia, F.
    Iannaccone, A.
    Chicchinelli, N.
    Morabito, A.
    Montanino, A.
    Rocco, G.
    Galetta, D.
    Montagna, S.
    Crino, L.
    Ludovini, V.
    Vincenzi, B.
    Barletta, E.
    Pinto, C.
    Ferrau, F.
    Botti, G.
    Piccirillo, M. C.
    Perrone, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Fenizia, F.
    Iannaccone, A.
    Chicchinelli, N.
    Morabito, A.
    Rocco, G.
    Galetta, D.
    Montagna, E. S.
    Crino, L.
    Ludovini, V.
    Vincenzi, B.
    Barletta, E.
    Pinto, C.
    Ferrau, F.
    Botti, G.
    Piccirillo, C.
    Perrone, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR-Mutant Lung Adenocarcinoma among Hispanics (Rbiop-CLICaP)
    Cardona, Andres
    Arrieta, Oscar
    Rojas, Leonardo
    Wills, Beatriz
    Reguart, Noemi
    Carranza, Hernan
    Vargas, Carlos
    Otero, Jorge
    Archila, Pilar
    Martin, Claudio
    Corrales, Luis
    Cuello, Mauricio
    Ortiz, Carlos
    Franco, Sandra
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S517 - S518
  • [46] MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
    Felip, E.
    Minotti, V.
    Soo, R.
    Wolf, J.
    Solomon, B.
    Tan, D. S. W.
    Ardizzoni, A.
    Lee, D. H.
    Sequist, L. V.
    Barlesi, F.
    Paz-Ares, L.
    Rodriguez-Abreu, D.
    Garcia Campelo, M. R.
    Sprauten, M.
    Djentuh, L. O'Sullivan
    Belli, R.
    Glaser, S.
    Zou, M.
    Giovannini, M.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2020, 31 : S829 - S830
  • [47] Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Xia, Jinjing
    Bai, Hao
    Yan, Bo
    Li, Rong
    Shao, Minhua
    Xiong, Liwen
    Han, Baohui
    ONCOTARGET, 2017, 8 (65) : 108522 - 108533
  • [48] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
    Johnson, Melissa
    Garassino, Marina Chiara
    Mok, Tony
    Mitsudomi, Tetsuya
    LUNG CANCER, 2022, 170 : 41 - 51
  • [49] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Yonesaka, Kimio
    Iwama, Eiji
    Hayashi, Hidetoshi
    Suzuki, Shinichiro
    Kato, Ryoji
    Watanabe, Satomi
    Takahama, Takayuki
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Sakai, Kazuko
    Azuma, Koichi
    Chiba, Yasutaka
    Atagi, Shinji
    Nishio, Kazuto
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [50] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Kimio Yonesaka
    Eiji Iwama
    Hidetoshi Hayashi
    Shinichiro Suzuki
    Ryoji Kato
    Satomi Watanabe
    Takayuki Takahama
    Junko Tanizaki
    Kaoru Tanaka
    Masayuki Takeda
    Kazuko Sakai
    Koichi Azuma
    Yasutaka Chiba
    Shinji Atagi
    Kazuto Nishio
    Isamu Okamoto
    Kazuhiko Nakagawa
    Scientific Reports, 9
12345